immunity News and Research

RSS

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

A recent report on the medRxiv* preprint server suggests that a single dose of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine could elicit higher titers of neutralizing antibodies, effectively acting as a booster dose, in people who have already been infected by the SARS-CoV-2.

13 May 2021

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

UMD receives new funding to stop infection from Lyme disease pathogens before it begins

The University of Maryland received new funding from the Steven & Alexandra Cohen Foundation to develop novel therapeutic strategies that have the potential to stop infection from Lyme disease pathogens before it begins.

13 May 2021

South Australian immunologist receives $3 million to accelerate work on Covid-19 vaccine

A leading South Australian immunologist has been awarded $3 million from the Federal Government to accelerate work on a locally developed Covid-19 vaccine, in what's anticipated to be the second line of defence against the virus.

13 May 2021

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

New research by a team at Northwestern University Feinberg School of Medicine, USA, suggests that the COVID-19 vaccine does not damage the placenta and may be safe to use during pregnancy.

13 May 2021

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Researchers in the UK have presented a multi-omics integrated blood atlas that delineates the host immune response in patients with coronavirus disease 2019 (COVID-19) of varying severity, providing a unique reference resource for the interpretation of datasets generated from interventional trials.

13 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Researchers identify six “words” used by specific immune cells to call up immune defense genes

UCLA life scientists have identified six "words" that specific immune cells use to call up immune defense genes -- an important step toward understanding the language the body uses to marshal responses to threats.

13 May 2021

AI helps assess patient's risk of regenerative outcomes after treatment of peri-implantitis

Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.

12 May 2021

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

The emergence of this variant highlighted the uneven pace of mutation and selection of variants. New bioinformatics tools are the need of the hour to clarify this and confirm a dynamic evolution by tracking the mutation rates of the spike protein. It generally takes 1 – 6 months for current variants causing COVID-19 case peaks and deaths to survive the pressure of selection.

11 May 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

A new study released as a bioRxiv* preprint tried to establish how tissues such as the upper respiratory tract (URT) – which harbor the virus and often act as the point of entry – are difficult to access for routine testing, but are responsive to vaccination.

11 May 2021

Study reveals acute immunologic changes in children with long COVID

Many reports are beginning to emerge on the ‘long COVID’ phenomenon. But a new study, released as a preprint on the medRxiv* server, describes, for the first time, immunologic changes observed in children with PASC.

11 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

The "key" to vaccine development depends on virus’ binding to human cells

New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the "key" to that development lies in the way the virus binds to human cells.

11 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Researchers from the US recently determined the sensitivity of the Quidel Sofia SARS Antigen FIA test (Sofia 2). They found a high viral load specimen that tested negative repeatedly while using this antigen test. The study is published on the preprint server, medRxiv.

10 May 2021

New spray protocol improves delivery of nasal antiseptic to reduce COVID-19 infection

A trip to visit family in Kolkata, India, put South Dakota State University assistant professor Saikat Basu in the middle of that country's second wave of COVID-19 infections.

10 May 2021

immunity News and Research

Antibodies generated by malaria cross-react with SARS-CoV-2

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

UMD receives new funding to stop infection from Lyme disease pathogens before it begins

South Australian immunologist receives $3 million to accelerate work on Covid-19 vaccine

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers identify six “words” used by specific immune cells to call up immune defense genes

AI helps assess patient's risk of regenerative outcomes after treatment of peri-implantitis

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

Study reveals acute immunologic changes in children with long COVID

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

The "key" to vaccine development depends on virus’ binding to human cells

Severe COVID-19 linked to genetic clotting predisposition

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

New spray protocol improves delivery of nasal antiseptic to reduce COVID-19 infection

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News